title: Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium.
abstract: Ubiquitin-mediated protein degradation is necessary for both increased ventricular mass and survival signaling for compensated hypertrophy in pressure-overloaded (PO) myocardium. Another molecular keystone involved in the hypertrophic growth process is the mammalian target of rapamycin (mTOR), which forms two distinct functional complexes: mTORC1 that activates p70S6 kinase-1 to enhance protein synthesis and mTORC2 that activates Akt to promote cell survival. Independent studies in animal models show that rapamycin treatment that alters mTOR complexes also reduces hypertrophic growth and increases lifespan by an unknown mechanism. We tested whether the ubiquitin-mediated regulation of growth and survival in hypertrophic myocardium is linked to the mTOR pathway. For in vivo studies, right ventricle PO in rats was conducted by pulmonary artery banding; the normally loaded left ventricle served as an internal control. Rapamycin (0.75 mg/kg per day) or vehicle alone was administered intraperitoneally for 3 days or 2 wk. Immunoblot and immunofluorescence imaging showed that the level of ubiquitylated proteins in cardiomyocytes that increased following 48 h of PO was enhanced by rapamycin. Rapamycin pretreatment also significantly increased PO-induced Akt phosphorylation at S473, a finding confirmed in cardiomyocytes in vitro to be downstream of mTORC2. Analysis of prosurvival signaling in vivo showed that rapamycin increased PO-induced degradation of phosphorylated inhibitor of κB, enhanced expression of cellular inhibitor of apoptosis protein 1, and decreased active caspase-3. Long-term rapamycin treatment in 2-wk PO myocardium blunted hypertrophy, improved contractile function, and reduced caspase-3 and calpain activation. These data indicate potential cardioprotective benefits of rapamycin in PO hypertrophy.
authors.affiliation: Cardiology Division of the Department of Medicine, Gazes Cardiac Research Institute, Medical University of South Carolina, South Caroline, USA.
authors.forename: Rebecca K
authors.initials: RK
authors.lastname: Harston
authors.forename: John C
authors.initials: JC
authors.lastname: McKillop
authors.forename: Phillip C
authors.initials: PC
authors.lastname: Moschella
authors.forename: An
authors.initials: A
authors.lastname: Van Laer
authors.forename: Lakeya S
authors.initials: LS
authors.lastname: Quinones
authors.forename: Catalin F
authors.initials: CF
authors.lastname: Baicu
authors.forename: Sundaravadivel
authors.initials: S
authors.lastname: Balasubramanian
authors.forename: Michael R
authors.initials: MR
authors.lastname: Zile
authors.forename: Dhandapani
authors.initials: D
authors.lastname: Kuppuswamy
mesh_terms: D000818:Animals; D002154:Calpain / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D006984:Hypertrophy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D008297:Male; D023421:Models, Animal; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology*; D011506:Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D054875:Ubiquitination / Q000187:drug effects* / Q000502:physiology
chemical_list: D007166:Immunosuppressive Agents; D051034:Inhibitor of Apoptosis Proteins; D011506:Proteins; C546845:mTOR protein, rat; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D002154:Calpain; D053148:Caspase 3; D020123:Sirolimus